ticlopidine has been researched along with Kidney Failure, Chronic in 37 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 9.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 7.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " The aim of the study was to assess the impact of clopidogrel on safety and efficacy in patients with renal dysfunction in non-ST elevation acute coronary syndromes." | 5.12 | Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. ( Hawken, S; Keltai, M; Lewis, BS; Mann, JF; Mehta, SR; Sitkei, E; Tonelli, M; Yusuf, S, 2007) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "The aim of the present study was to evaluate clopidogrel treatment after incident myocardial infarction (MI) in patients with and without chronic kidney disease (CKD)." | 3.80 | Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study. ( Blicher, TM; Hommel, K; Kamper, AL; Kristensen, SL; Madsen, M; Olesen, JB; Torp-Pedersen, C, 2014) |
| " The study was performed in healthy subjects, patients with coronary artery disease, patients with end-stage renal disease, and patients with acute coronary syndrome after treatment with prasugrel or clopidogrel." | 3.76 | A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. ( Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ, 2010) |
| "In this single-center, prospective, randomized pharmacodynamic study, 52 ESRD patients on HD were prescribed clopidogrel (300mg loading dose [LD], then 75mg daily), standard-dose ticagrelor (180mg LD, then 90mg twice daily), or low-dose ticagrelor (90mg LD, then 90mg daily) for 14days." | 2.84 | The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. ( Ihm, CG; Jeong, KH; Kim, JB; Kim, JS; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS, 2017) |
| "Also, 36 patients with chronic renal failure (60 +/- 5 years) were divided into 2 groups according to their daily dose of clopidogrel: a daily dose of 75 mg of clopidogrel for 30 days (group II, n = 18) or a daily dose of 150 mg (group III, n = 18)." | 2.74 | A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. ( Hwang, SH; Kang, WY; Kim, W; Park, CS; Park, SH, 2009) |
| "People with end-stage renal disease (ESRD) often require either the formation of an arteriovenous fistula (AVF) or an interposition prosthetic arteriovenous graft (AVG) for haemodialysis." | 2.72 | Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Kamarizan, MFA; Mohamed, I, 2021) |
| "End-stage renal disease (ESRD) patients often require either the formation of an arteriovenous (AV) fistula or an AV interposition prosthetic shunt for haemodialysis." | 2.52 | Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. ( Da Silva, A; Tanner, NC, 2015) |
| "She developed aplastic anemia seven weeks after initiation of ticlopidine." | 2.41 | Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review. ( Ammash, Z; Dabajah, B; Mourad, FH; Nasrallah, A; Taher, A, 2000) |
| "Clopidogrel and ticlopidine, sometimes in combination with ASA, are associated with a low risk of bleeding during renal transplantation and does not seem to be a contraindication for renal transplant surgery." | 1.40 | Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study. ( Abramowicz, D; Benahmed, A; Broeders, N; Donckier, V; Ghisdal, L; Hoang, AD; Kianda, M; Le Moine, A; Lemy, A; Madhoun, P; Massart, A; Mikhalski, D; Racapé, J; Sadis, C; Wissing, M, 2014) |
| "Patients with ESRD are at higher risk for coronary artery disease (CAD) and also their post-interventional outcome is worse compared to patients with normal renal function." | 1.40 | Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study. ( Bocksch, W; Fateh-Moghadam, S; Gawaz, M; Geisler, T; Htun, P; Kan, T; Mueller, E; Pohle, C; Schindler, R, 2014) |
| "Ticlopidine hydrochloride was administered at a dose of 200 mg daily for 4 weeks." | 1.31 | Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis. ( Akai, Y; Ando, Y; Asano, Y; Furuya, H; Inoue, M; Kusano, E; Tabei, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (10.81) | 18.7374 |
| 1990's | 2 (5.41) | 18.2507 |
| 2000's | 13 (35.14) | 29.6817 |
| 2010's | 17 (45.95) | 24.3611 |
| 2020's | 1 (2.70) | 2.80 |
| Authors | Studies |
|---|---|
| Mohamed, I | 1 |
| Kamarizan, MFA | 1 |
| Da Silva, A | 2 |
| Kim, JS | 1 |
| Woo, JS | 2 |
| Kim, JB | 2 |
| Kim, WS | 2 |
| Lee, TW | 2 |
| Kim, KS | 2 |
| Ihm, CG | 2 |
| Kim, W | 4 |
| Jeong, KH | 2 |
| Benahmed, A | 1 |
| Kianda, M | 1 |
| Ghisdal, L | 1 |
| Broeders, N | 1 |
| Massart, A | 1 |
| Lemy, A | 1 |
| Mikhalski, D | 1 |
| Hoang, AD | 1 |
| Donckier, V | 1 |
| Sadis, C | 1 |
| Le Moine, A | 1 |
| Madhoun, P | 1 |
| Racapé, J | 1 |
| Wissing, M | 1 |
| Abramowicz, D | 1 |
| Htun, P | 1 |
| Kan, T | 1 |
| Mueller, E | 1 |
| Pohle, C | 1 |
| Schindler, R | 1 |
| Geisler, T | 1 |
| Gawaz, M | 1 |
| Bocksch, W | 1 |
| Fateh-Moghadam, S | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Lai, WT | 1 |
| Huang, YB | 1 |
| Kakisis, JD | 1 |
| Vassilas, K | 1 |
| Antonopoulos, C | 1 |
| Sfyroeras, G | 1 |
| Moulakakis, K | 1 |
| Liapis, CD | 1 |
| Blicher, TM | 1 |
| Hommel, K | 1 |
| Kristensen, SL | 1 |
| Torp-Pedersen, C | 1 |
| Madsen, M | 1 |
| Kamper, AL | 1 |
| Olesen, JB | 1 |
| Williams, JM | 1 |
| Tuttle-Newhall, JE | 1 |
| Schnitzler, M | 1 |
| Dzebisashvili, N | 1 |
| Xiao, H | 1 |
| Axelrod, D | 1 |
| Mogal, H | 1 |
| Lentine, KL | 1 |
| Cho, JH | 1 |
| Bouatou, Y | 1 |
| Samer, CF | 1 |
| Fontana, P | 1 |
| Daali, Y | 1 |
| Desmeules, J | 1 |
| Tanner, NC | 1 |
| Lee, JY | 1 |
| Moon, IT | 1 |
| Lee, HY | 1 |
| Lee, HL | 1 |
| Han, DS | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Hsu, CY | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Chan, KE | 1 |
| Lazarus, JM | 1 |
| Thadhani, R | 1 |
| Hakim, RM | 1 |
| Kittisupamongkol, W | 1 |
| Park, SH | 1 |
| Park, CS | 1 |
| Kang, WY | 1 |
| Hwang, SH | 1 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 1 |
| Jakubowski, JA | 1 |
| Li, YG | 1 |
| Small, DS | 1 |
| Payne, CD | 1 |
| Tomlin, ME | 1 |
| Luo, J | 1 |
| Winters, KJ | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| Geara, AS | 1 |
| Ayoub, I | 1 |
| Abi Rached, J | 1 |
| Siddique, MN | 1 |
| Ghimire, P | 1 |
| El-Sayegh, S | 1 |
| Alexopoulos, D | 1 |
| Xanthopoulou, I | 1 |
| Plakomyti, TE | 1 |
| Goudas, P | 1 |
| Koutroulia, E | 1 |
| Goumenos, D | 1 |
| Kusano, E | 1 |
| Inoue, M | 1 |
| Akai, Y | 1 |
| Furuya, H | 1 |
| Ando, Y | 1 |
| Tabei, K | 1 |
| Asano, Y | 1 |
| Kaufman, JS | 1 |
| O'Connor, TZ | 1 |
| Zhang, JH | 1 |
| Cronin, RE | 1 |
| Fiore, LD | 1 |
| Ganz, MB | 1 |
| Goldfarb, DS | 1 |
| Peduzzi, PN | 1 |
| Igaki, N | 1 |
| Matsuda, T | 1 |
| Yatani, H | 1 |
| Kawaguchi, T | 1 |
| Kida, A | 1 |
| Yanase, K | 1 |
| Moriguchi, R | 1 |
| Sakai, M | 1 |
| Tamada, F | 1 |
| Goto, T | 1 |
| Akcay, A | 1 |
| Kanbay, M | 1 |
| Agca, E | 1 |
| Sezer, S | 1 |
| Ozdemir, FN | 1 |
| Janicki, K | 1 |
| Bojarska-Szmygin, A | 1 |
| Pietura, R | 1 |
| Janicka, L | 1 |
| Suh, SY | 1 |
| Rha, SW | 1 |
| Kim, JW | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Ro, YM | 1 |
| Gruberg, L | 1 |
| Beyar, R | 1 |
| Keltai, M | 1 |
| Tonelli, M | 1 |
| Mann, JF | 1 |
| Sitkei, E | 1 |
| Lewis, BS | 1 |
| Hawken, S | 1 |
| Mehta, SR | 1 |
| Yusuf, S | 1 |
| Mambelli, E | 1 |
| Mancini, E | 1 |
| Casanova, S | 1 |
| Di Felice, A | 1 |
| Santoro, A | 1 |
| Méndez Martín, A | 1 |
| Ortiz González, A | 1 |
| Gutiérrez González, JR | 1 |
| Kobayashi, K | 1 |
| Maeda, K | 1 |
| Koshikawa, S | 1 |
| Kawaguchi, Y | 1 |
| Shimizu, N | 1 |
| Naito, C | 1 |
| Windus, DW | 1 |
| Santoro, SA | 1 |
| Atkinson, R | 1 |
| Royal, HD | 1 |
| Kamper, AM | 1 |
| Lins, RL | 1 |
| Zachée, P | 1 |
| Van Bergen, S | 1 |
| Hosten, S | 1 |
| Daelemans, R | 1 |
| Taher, A | 1 |
| Ammash, Z | 1 |
| Dabajah, B | 1 |
| Nasrallah, A | 1 |
| Mourad, FH | 1 |
| Griffanti-Bartoli, F | 1 |
| Altomonte, F | 1 |
| Pitton, L | 1 |
| Armani, U | 1 |
| Piana, A | 1 |
| Traietti, P | 1 |
| Chiappini, MG | 1 |
| Belfiglio, A | 1 |
| Bartoli, R | 1 |
| Bologna, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency[NCT00067119] | Phase 3 | 649 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| Impact of Vitamin D on Arteriovenous Fistulae Maturation Among ESRD Patients[NCT00912782] | 52 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease[NCT01001351] | Phase 1/Phase 2 | 89 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Maturation of an AVF is the ability to stick the AVF with two large bore needles at ≥ 6 consecutive dialysis sessions, and achievement of an AVF blood flow >300 ml/min, assessed at six months following AVF creation. (NCT00912782)
Timeframe: 6 months
| Intervention | percentage of group (Number) |
|---|---|
| Placebo | 50 |
| Cholecalciferol | 40 |
(NCT00912782)
Timeframe: 10 weeks
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Serum 25 (OH) D | Serum Calcium | |
| Cholecalciferol | 53.4 | 8.8 |
| Placebo | 18.4 | 9.1 |
6 reviews available for ticlopidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Fish Oils; Graft Occlusion, Vascular; Humans; | 2021 |
Wandering stent within the pulmonary circulation.
Topics: Aged, 80 and over; Angiography, Digital Subtraction; Anticoagulants; Arteriovenous Shunt, Surgical; | 2014 |
Evidence-Based Choice of P2Y12 Inhibitors in End Stage Renal Disease Patients: A Mini-Review.
Topics: Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Kidney Failure, Chronic; Platelet | 2015 |
Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.
Topics: Arteriovenous Shunt, Surgical; Chemotherapy, Adjuvant; Humans; Kidney Failure, Chronic; Platelet Agg | 2015 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review.
Topics: Aged; Aged, 80 and over; Anemia, Aplastic; Aspirin; Bone Marrow Cells; Coronary Disease; Female; Gas | 2000 |
7 trials available for ticlopidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis.
Topics: Adenosine; Adult; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Kidney Failur | 2017 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Human | 2015 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.
Topics: Analysis of Variance; Clopidogrel; Creatinine; Dose-Response Relationship, Drug; Female; Humans; Kid | 2009 |
Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis.
Topics: Aged; Aspirin; Catheters, Indwelling; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; F | 2003 |
Preventive effects of Ticlopidine on the incidence of late A-V fistula thrombosis complications in haemodialyses patients.
Topics: Adult; Aged; Arteriovenous Shunt, Surgical; Drug Administration Schedule; Female; Follow-Up Studies; | 2003 |
Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.
Topics: Aged; Angina, Unstable; Clopidogrel; Coronary Disease; Creatinine; Double-Blind Method; Female; Glom | 2007 |
Safety of combining ticlopidine with nadroparin in the routine treatment of chronic hemodialysis patients.
Topics: Drug Combinations; Humans; Kidney Failure, Chronic; Nadroparin; Platelet Aggregation Inhibitors; Ren | 1997 |
24 other studies available for ticlopidine and Kidney Failure, Chronic
| Article | Year |
|---|---|
Ticlopidine and clopidogrel, sometimes combined with aspirin, only minimally increase the surgical risk in renal transplantation: a case-control study.
Topics: Aspirin; Blood Loss, Surgical; Case-Control Studies; Clopidogrel; Dose-Response Relationship, Drug; | 2014 |
Haemodialysis impairs clopidogrel but not aspirin responsiveness in patients with end-stage renal disease. Results of a pilot study.
Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hum | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
Benefit of clopidogrel therapy in patients with myocardial infarction and chronic kidney disease-a Danish nation-wide cohort study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Cohort Studies; | 2014 |
Clopidogrel use as a risk factor for poor outcomes after kidney transplantation.
Topics: Cardiovascular Diseases; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; G | 2014 |
Successful Management of Recurrent Colon Ulcer in Hemodialysis Patient after Conversion to Peritoneal Dialysis.
Topics: Aspirin; Colon; Colonic Diseases; Colonoscopy; Drug Therapy, Combination; Gastrointestinal Hemorrhag | 2015 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.
Topics: Aged; Anticoagulants; Clopidogrel; Cohort Studies; Confidence Intervals; Female; Humans; Internation | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; | 2010 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Does hemodialysis affect clopidogrel resistance as measured by VerifyNow P2Y12 test?
Topics: Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Drug Resistance; Humans; Kidney Failur | 2011 |
Ticagrelor in clopidogrel-resistant patients undergoing maintenance hemodialysis.
Topics: Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Drug Resistance; Female; Humans; K | 2012 |
Effect of ticlopidine hydrochloride on erythropoietin-induced rise in blood pressure in patients on maintenance hemodialysis.
Topics: Adult; Blood Pressure; Erythropoietin; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; | 2002 |
Deep venous thrombosis, myocardial infarction, and occlusion of vascular access associated with heparin-induced thrombocytopenia in a diabetic hemodialysis patient.
Topics: Anticoagulants; Catheters, Indwelling; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fi | 2003 |
Neutropenia due to clopidogrel in a patient with end-stage renal disease.
Topics: Adult; Clopidogrel; Humans; Kidney Failure, Chronic; Male; Neutropenia; Platelet Aggregation Inhibit | 2004 |
Neutropenia associated with clopidogrel use in a patient with chronic renal failure who underwent percutaneous coronary and peripheral intervention.
Topics: Adult; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Clopidogrel; Fatal Outcome; Female; Gra | 2006 |
End-stage renal disease and drug-eluting stents: one small step forward.
Topics: Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Coronary Restenosis; Humans; I | 2006 |
Severe ticlopidine-induced cholestatic syndrome.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Humans; Kidney Failure, Chronic; | 2007 |
[Changes in arterial blood gases after hemodialysis and the influence of platelet antiaggregation].
Topics: Adult; Blood Gas Analysis; Carbon Dioxide; Female; Humans; Kidney Failure, Chronic; Male; Middle Age | 1984 |
Antithrombotic therapy with ticlopidine in chronic renal failure patients on maintenance hemodialysis--a multicenter collaborative double blind study.
Topics: Adult; Aged; Blood Urea Nitrogen; Chlorides; Creatinine; Double-Blind Method; Female; Fibrinolytic A | 1980 |
Effects of antiplatelet drugs on dialysis-associated platelet deposition in polytetrafluoroethylene grafts.
Topics: Arteriovenous Shunt, Surgical; Aspirin; Blood Vessel Prosthesis; Humans; Indium Radioisotopes; Kidne | 1997 |
[Use of a new platelet aggregation inhibitor, ticlopidine, in hemodialysis].
Topics: Adult; Aged; Blood Coagulation Disorders; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged | 1979 |
[Effects of the treatment with ticlopidine in hemodialyzed patients].
Topics: Heparin; Humans; Kidney Failure, Chronic; Platelet Aggregation; Platelet Aggregation Inhibitors; Ren | 1988 |